Next Article in Journal
Marine Compounds and Autophagy: Beginning of a New Era
Next Article in Special Issue
Heterologous Expression of the Nybomycin Gene Cluster from the Marine Strain Streptomyces albus subsp. chlorinus NRRL B-24108
Previous Article in Journal
Biochemical Characterization and Degradation Pattern of a Novel Endo-Type Bifunctional Alginate Lyase AlyA from Marine Bacterium Isoptericola halotolerans
Previous Article in Special Issue
Harnessing Marine Biocatalytic Reservoirs for Green Chemistry Applications through Metagenomic Technologies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 16
Issue 8
10.3390/md16080259
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Characterization of the Jomthonic Acids Biosynthesis Pathway and Isolation of Novel Analogues in Streptomyces caniferus GUA-06-05-006A

by
Raúl García-Salcedo
1,2,3,
Rubén Álvarez-Álvarez
1,2,
Carlos Olano
1,2,
Librada Cañedo
3,
Alfredo F. Braña
1,2,
Carmen Méndez
1,2,
Fernando De la Calle
3 and
José A. Salas
1,2,*
1
Department of Functional Biology and University Institute of Oncology of Principado de Asturias (U.I.O.P.A), University of Oviedo, 33006 Oviedo (Asturias), Spain
2
Institute for Health Research of Principado de Asturias (IHRPA), 33006 Oviedo (Asturias), Spain
3
Drug Discovery Area, PharmaMar S.A. Avda. de los Reyes 1, 28770 Colmenar Viejo (Madrid), Spain
*
Author to whom correspondence should be addressed.
Mar. Drugs 2018, 16(8), 259; https://doi.org/10.3390/md16080259
Submission received: 9 July 2018 / Revised: 26 July 2018 / Accepted: 28 July 2018 / Published: 31 July 2018
(This article belongs to the Special Issue Microbial Gene Clusters of Marine Origin)
Browse Figures
Versions Notes

Abstract

:
Jomthonic acids (JAs) are a group of natural products (NPs) with adipogenic activity. Structurally, JAs are formed by a modified β-methylphenylalanine residue, whose biosynthesis involves a methyltransferase that in Streptomyces hygroscopicus has been identified as MppJ. Up to date, three JA members (A–C) and a few other natural products containing β-methylphenylalanine have been discovered from soil-derived microorganisms. Herein, we report the identification of a gene (jomM) coding for a putative methyltransferase highly identical to MppJ in the chromosome of the marine actinobacteria Streptomyces caniferus GUA-06-05-006A. In its 5’ region, jomM clusters with two polyketide synthases (PKS) (jomP1, jomP2), a nonribosomal peptide synthetase (NRPS) (jomN) and a thioesterase gene (jomT), possibly conforming a single transcriptional unit. Insertion of a strong constitutive promoter upstream of jomP1 led to the detection of JA A, along with at least two novel JA family members (D and E). Independent inactivation of jomP1, jomN and jomM abolished production of JA A, JA D and JA E, indicating the involvement of these genes in JA biosynthesis. Heterologous expression of the JA biosynthesis cluster in Streptomyces coelicolor M1152 and in Streptomyces albus J1074 led to the production of JA A, B, C and F. We propose a pathway for JAs biosynthesis based on the findings here described.

1. Introduction

The marine environment is a valuable source of natural products (NPs) with increasing medical importance [1,2]. The relevance and success of screening programs aimed at discovering new molecules with pharmaceutical application from the marine environment has been validated by the development and marketing of various NPs as analgesic [3], antiviral [4] and antitumor drugs [5]. This fact, along with the exponentially growing number of reported bioactive agents isolated from marine invertebrates and microorganisms [6,7], points to oceans as a preeminent environment for the supply of novel therapeutic chemicals. Although marine invertebrates such as sponges [8,9] are renowned drug discovery targets, in many instances the true producer of the relevant NP are symbiotic microorganisms, often bacteria and cyanobacteria, which represent a worthy exploring source of novel and structurally diverse chemical entities [10,11,12,13].
In the last decade, much attention has been given to microbial genomics regarding the potential of microorganisms as producers of bioactive metabolites [14,15,16]. Many whole-genome sequencing projects from both marine- and soil-derived microorganisms have uncovered a wealth of orphan genes related to secondary metabolism such as polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS) [17,18]. This way, the blooming number of microbial genomes and metagenomic data from different environments [19,20,21] might contribute to innovative achievements on NP research and raises new prospects for the discovery of novel treatments for emerging disorders [22,23,24]. Genomic analysis of known and under study microorganisms reveals that the number of potential secondary metabolite gene clusters harbored by their respective chromosomes surpasses the amount of compounds detected under conventional laboratory conditions, indicating that microbial capability to provide chemicals of medical interest could be far greater than expected [25,26,27]. This has prompted the development of a series of molecular- and cultivation-based approaches intended to uncover and exploit the natural chemical potential of candidate microorganisms by eliciting the expression of silent or poorly expressed gene clusters [28,29,30,31,32]. Alone or in combination, different pathway-specific genome mining strategies such as gene mutation, insertion of constitutive promoters in front of key gene operons or direct cloning and subsequent heterologous expression of orphan gene clusters, might help to uncover the metabolite(s) biosynthesized by any given cryptic gene cluster. These and many other molecular strategies, along with the development of next-generation whole-genome sequencing systems and bioinformatics sequence analysis platforms, have given birth to the so-called field of genomics-driven natural product discovery [24,33,34]. Research on this field has made feasible the discovery of a wave of novel microbial NPs biosynthesized by gene clusters regarded up to now as cryptic [35,36,37,38,39,40,41].
Herein, we report on the activation of a cryptic PKS-NRPS hybrid gene cluster in the chromosome of the marine actinobacteria Streptomyces caniferus GUA-06-05-006A. This has enabled the identification of three novel metabolites belonging to the jomthonic acid (JA) family of NPs. Up to date, only three members (JA A–C) of this family of molecules have been reported [42,43]. We describe the isolation and structural determination of two new JA A derivatives, and the identification of additional potential related compounds.

2. Results

2.1. Identification of the Jomthonic Acid Gene Cluster

Previous identification and characterization in the marine actinobacteria S. caniferus GUA-06-05-006A of the promising antitumor compounds PM100117 and PM100118 biosynthesis gene cluster (BGC) [44], aimed us to further investigate the chemical diversity enclosed in this strain. Of the 32 BGCs potentially involved in the production of secondary metabolites detected after sequencing of the genome of S. caniferus GUA-06-05-006A, only two BGCs contain PKS–NRPS hybrid genes [44]. One of these PKS–NRPS BGCs (Figure 1, Table 1) caught our attention because it entails a large operon that included a gene (jomM) coding for a putative methyltransferase highly identical to MppJ, the enzyme responsible for the biosynthesis of βMePhe in Streptomyces hygroscopicus [45]. To discover the compound(s) coded by this BGC, we inserted the constitutive promoter ermE*p upstream of the PKS gene jomP1 (Figure 1). Ultra Performance Liquid Chromatography (UPLC) analysis of metabolite production in the resulting strain, G-permE*, revealed the increased biosynthesis, relative to wild type, of three compounds (1–3, Figure 2A) showing identical UV spectra, with a maximum absorption wavelength at 264 nm. Consistent with this observation, production of 1–3 was abolished upon insertional inactivation of PKS gene jomP1 or NRPS gene jomN (Figure 2A), thus confirming the involvement of both genes in 1–3 biosynthesis. These compounds were purified and subjected to structural analysis by nuclear magnetic resonance NMR (Supplementary file 1). The chemical structure of 1 and 2 corresponded to novel analogues of JA A, a previously identified natural product with adipogenic activity produced by Streptomyces sp. BB47 [42]. Structurally, JA A (peak 3, UPLC Rt = 5.209 min, m/z 388.2141[M + H]+ (calculated for C22H30NO5 388.2118)), consists of a βMePhe residue with its amino and carboxyl group attached to a short polyketide chain and to a hydroxyacid unit, respectively (Figure 2B). The chemical structure of 1 (UPLC Rt = 4,264 min, m/z 516.2709 [M + H]+ (calculated for C27H38N3O7 516.2704)) is that of JA A with a glutamine residue at C21 in the hydroxyacid part. Compound 2 (UPLC Rt = 4,411 min, m/z 404.2099 [M + H]+ (calculated for C22H30NO6 404. 2079)) is derived from 3 by polyketide chain hydroxylation at C1. Given the structural relationship of compounds 1 and 2 with JA A, hereinafter, they will be referred to as JA D and E, respectively.

2.2. Bioinformatics Analysis of the Jomthonic Acid Gene Cluster and Proposed Biosynthesis Pathway

Polyketide biosynthesis: The predicted JAs BGC spans 55kb and contains 38 ORFs, which includes two putative PKS genes, jomP1 and jomP2 (Figure 1 and Table 1), presumably involved in the biosynthesis of the JA polyketide chain. JomP1 and JomP2 show the closest similarity with PKS proteins StiA (57%) and StiC (49%), respectively, which participate in the biosynthesis of stigmatellin in the myxobacteria Stigmatella aurantica Sga15 [46]. Besides, both proteins show resemblance with putative PKS enzymes from other myxobacteria members and several species of cyanobacteria. Bioinformatics analysis detected in JomP1 an uncommon PKS domain pattern, consisting of two ACP and two contiguous AT (AT1 and AT2) domains, distributed as follows: ACP-KS-AT1-AT2-KR-ACP (Figure 3). This pattern is a rare finding previously described in myxobacteria [46,47,48,49]. In these microorganisms, the presence of two adjacent AT domains has been linked to the specificity of the loading domain for unusual initiating units, alternative to malonyl- and methylmalonyl-CoA [46]. It has been conjectured that in the biosynthesis of myxalamid [48], soraphen [49] and myxothiazol [47], the first AT domain is responsible for loading the unusual starter units, isobutyryl-CoA/2-methyl-butyryl-CoA, benzoyl-CoA and methylbutyryl-CoA, respectively, while the second AT domain is involved in the transfer of the first extension unit, typically malonyl- or methylmalonyl-CoA. However, this assumption might not stand for the JomP1 AT2 domain, which might be inactive due to the substitution of Ser-7 and Gln-8 for Gly and His, respectively, in the conserved sequence domain GqgSQ (Supplementary file 2: Figure S22) that lies close to the active site pocket in the AT domain 3D model [50,51]. According to these observations, it seems reasonable to propose the transfer by AT1 of 2-methyl-2-eno-butyryl-CoA (MEB-CoA) as the carboxylic acid incorporated by JomP1 (Figure 3). Furthermore, a certain degree of flexibility of AT1 could explain the biosynthesis of other JAs previously described [42,43]. In this hypothetical model, no role can be envisaged for the JomP1 KR domain. The biosynthesis of the JAs polyketide chain is completed by PKS JomP2, which contains an AT domain with predicted specificity for malonyl-CoA, KR and DH domains.
Methylphenylalanine biosynthesis: A (2S, 3R) βMePhe residue constitutes the structural core of JAs. Biosynthesis of this moiety presumably requires activity of a methyltransferase enzyme. Genetic experiments in Streptomyces hygroscopicus NRRL30439 have shown methyltransferase MppJ to catalyze phenylalanine β-methylation in mannopeptimycin biosynthesis [45]. Besides, later in vitro studies on MppJ activity have shown that it methylates the benzylic C atom of phenylpyruvate instead of phenylalanine or the mannopeptimycin aglycone F [52]. Gene jomM in the JAs BGC codes for a putative methyltranferase 55% identical to MppJ. UPLC analysis of culture extracts from deletion mutant ∆jomM showed loss of 1–3 production (Figure 4), confirming involvement in JAs biosynthesis, conceivably catalyzing phenylalanine β-methylation. JA biosynthesis was restored in ∆jomM upon jomM re-introduction (Supplementary file 2: Figure S23).
2-methyl-3-hydroxybutyrate biosynthesis and other gene functions: Various branched-chain fatty acids, such as 2-methylbutyrate, can be generated in bacteria from amino acid fermentation. Moreover, interconversion between 2-methy-3-hydroxylbutyrate (MHB) and leucine has been described in anaerobic bacteria [53,54]. Hence, although based on sequence identity, no gene functions remotely related to MHB biosynthesis are comprised within the JA BGC; certain primary metabolism reactions might supply this structural moiety.
The JA BGC also comprises NRPS jomN, containing a condensation and an adenylation domain, which is postulated to be the candidate enzyme to catalyze βMePhecondensation with the polyketide chain. MbtH-like protein JomB and thioesterase JomT complete the proteins presumably required for JAs biosynthesis. Based on various studies on MbtH-like protein function [55,56], JomB is possibly required for βMePhe activation during its adenylation by JomN. JomT might be required to cleave and offload JA F from the JomN PCP domain (Figure 3).
Hypothetical model for JAs assembly: Polyketide biosynthesis might be commenced by JomP1 which, despite containing two ACP and two AT domains, would only be responsible for the loading of the starting carboxylic acid MEB (Figure 3). As explained above, no extension reaction is presumed to be catalyzed by JomP1 AT2. JomP2 would then extend the polyketide chain with malonate, with a double bond formation due to the consecutive activity of its KR and DH domain. Next, NRPS JomN would perform condensation of βMePhe with the polyketide molecule to form JA F. Subsequent addition of MHB to form JA A might require JA F release from JomN, a reaction probably catalyzed by JomT. Notwithstanding, the enzymatic activity (X1) required to transfer the third JAs structural moiety MHB to JA F (Figure 3) is unknown and possibly coded elsewhere in the genome as, based on sequence identity, no gene functions suited to accomplish this reaction have been identified within the JA BGC. Likewise, the JA BGC does not code for enzymatic activities related to glutamine transfer (X2) to produce JA D and JA hydroxylation (X3) to produce JA E (Figure 3). Gene candidates conceivably involved is those reaction are orf31 and orf9, which encode for putative proteins with glutamine binding lipoprotein and monooxygenase activity, respectively. Nevertheless, deletion of these genes does not have any effect on JA D and E production (Figure 4).

2.3. Cluster Boundaries Analysis

Flanking the JAs BGC there are four orfs coding for putative transcriptional regulators belonging to the GntR (orf29), MarR (orf20), LuxR (orf16) and AraC (orf8) families of transcription factors. To examine whether or not these putative regulators take part in JAs biosynthesis control, we generated a series of single gene deletion strains. UPLC metabolite analysis of the resulting mutants ∆orf29-gntR, ∆orf20-marR and ∆orf16-luxR, revealed no significant alteration of JAs biosynthesis with respect to wild type cells (Figure 5A). By contrast, mutant ∆orf8-araC showed a slight increase of 1 and 2 production, concomitant with a diminished JA A level. As a second assessment of the potential involvement of these genes in JAs biosynthesis, they were ectopically expressed under the control of the constitutive promoter ermE*p from the integrative plasmid pSETk. The resulting constructs pSAraC, pSLuxR, pSMarR and pSGntRwere were transferred to wild type S. caniferus GUA-06-05-006A to produce the recombinant strains G-pSAraC, G-pSLuxR, G-pSMarR and G-pSGntR, respectively, which were likewise subjected to metabolite production analysis (Figure 5B). Overexpression of orf29 (G-pSGntR) resulted in JAs biosynthesis abrogation and a severe impairment of PM100117/18 production, indicating the pleiotropic effect possibly exerted by this gene on metabolite production. This observation, along with the unaltered biosynthesis of compounds 1 and 2 upon orf29 deletion, makes us to consider that this orf lies outside the JAs biosynthesis gene cluster. Pleiotropic effects on PM100117/18 biosynthesis are similarly observed in recombinant strains G-pSLuxR (orf16) and G-pSMarR (orf20), but neither these strains nor G-pSAraC (orf8) showed altered 1 and 2 biosynthesis levels relative to control. Under the light of these observations, it is not possible to determine whether orf8 and orf29 play a direct role or simply exert a pleiotropic effect on JAs biosynthesis.
The right boundary of the JAs gene cluster is thus defined by jomM, as the adjacent orf16 does not seem to be involved in JAs biosynthesis. This side of the cluster also comprises putative gene functions connected to chemical detoxification (orf21 and orf30), DNA cleavage and repair (orf19 and orf22) and primary metabolism processes, such as sugar metabolism and transport (orf24-orf28) and nitrogen metabolism (orf31 and orf32). The left limit of the cluster might be defined by jomP1, whose adjacent orf14 and orf15 encode for hypothetical and unassigned function proteins, respectively. Besides, this flank of the JAs gene cluster contains miscellanea of hypothetical gene functions related to virulence (orf4, orf7 and orf11), cell division (orf3) and cell signaling (orf10) among others (Table 1).

2.4. Heterologous Expression of the JAs BGC

In order to confirm the involvement of the proposed gene cluster in JA biosynthesis, a DNA fragment spanning from orf9 to orf24 was cloned using the transformation-associated recombination (TAR) cloning system [37] and the resulting construct, pJATAR, was transferred to the heterologous hosts Streptomyces coelicolor M1152 and Streptomyces albus J1074 to produce strains Sc-pJATAR and Sa-pJATAR, respectively. These strains were fermented in a culture medium that favors secondary metabolite biosynthesis in their respective backgrounds. Analysis by UPLC of organic extracts from the resulting cultures did not detect traces of JAs (Figure 6). This result led us to hesitate on the expression in the heterologous hosts of genes presumably required for JAs biosynthesis. Thus, we manipulated pJATAR to insert the constitutive promoter ermE*p in front of jomP1 to compel transcription of genes jomP1-jomM, which possibly constitutes a single transcriptional unit. Likewise, the resulting plasmid, pJATARe, was introduced in S. coelicolor M1152 and S. albus J1074, generating strains Sc-pJATARe and Sa-pJATARe, respectively. Following UPLC analysis of metabolite production the presence of JA A biosynthesis was detected in both recombinant strains (Figure 6). Besides, based on absorption spectra resemblance, strain Sa-pNTARe produced two additional potential JAs family members, peaks 1a and 2a (Figure 6B). Mass spectra of these products are shown in Supplementary file 2: Figure S24. Molecular weight of product 2a matched that of JA B/C (m/z374 [M+H]+) (Figure 6C), which remained undetected in the natural producer S. caniferus GUA-06-05-006A (Figure 2). Later metabolite analysis of 5-fold concentrated culture extracts from the S. caniferus GUA-06-05-006A derivative strain G-permE* led to the detection, by absorption spectra resemblance, of other potential JA candidates, including JA F (Supplementary file 2: Figure S25), but not JA B/C. Given their low production levels, purification of these compounds did not yield the product quantities required to carry out NMR analysis.

3. Discussion

Given their adipogenic activity, JAs constitute a promising family of NPs in metabolic disorders research [57,58,59]. JA’s chemical structure contains interesting structural moieties also reported in other metabolites. For instance, the JA A short polyketide chain is identical to that of salinamide C from Streptomyces sp. CNB-091 [60] and daldinin F from Hypoxylonfuscum [61]. Likewise, βMePhe is an unusual non-proteinogenic amino acid previously described as part of the altemicidin derivative SB-203208 [62], bottromycins [63], AK toxin [64], homaomycin [65] and mannopeptimycin [66]. However, only the latter two compounds share with JAs the 3R configuration of the βMePhe stereocenter.
Following a molecular elicitation strategy, we have identified the JA BGC, which has been characterized based on bioinformatics analysis and genetic engineering data. The proposed cluster covers 17.1 Kb and contains six biosynthesis genes comprised between jomP1 and jomM, coding for putative functions required for polyketide biosynthesis and phenylalanine methylation. PKS JomP1 displays an uncommon structure, consisting of two ACP domains and two adjacent AT domains, up to date only reported in members of myxobacteria [46,47,48,49]. For similar myxobacterial PKS genes, a mechanism by which the first AT domain transfers an unconventional starting unit and the second AT domain transfer either malonyl- or methylmalonyl-CoA has been proposed. However, if JomP1 operated through this mechanism, it would be arduous to assess the type of starting and elongation units employed to synthesize the short polyketide chain present in JAs. Tentatively, we could postulate malonyl- and methylmalonyl-CoA as starting and extension molecules, respectively, which along with latter condensation to malonyl-CoA catalyzed by JomP2 could generate the JA polyketide chain with an extra hydroxyl group at C2 (Supplementary file 2: Figure S26). Instead, based on the sequence of conserved domain, we have considered plausible the inactivity of AT2 and transfer of MEB-CoA by AT1 domain (Figure 3).
Despite the absence of information on various gene functions presumably required for JA biosynthesis, we have intuitively outlined a biosynthesis pathway (Figure 3). Although no traces of JA B and C have been detected in S. caniferus GUA-06-05-006A, biosynthesis of both compounds could occur through similar reaction steps as JA A when 2-eno-butyrate and 3-hydroxybutyrate are available as substrates for JomP1 and enzyme X1, respectively (Figure 3). Based on predicted gene functions, enzymes relevant to MHB transfer seem to be absent from the predicted JAs BGC. Thus, according to the enzymatic activities encoded within the proposed biosynthesis pathway, it could be reasonable to consider JA F as the true pathway end product, and the other JAs family members as pathway shunt metabolites. Interestingly, heterologous expression of the BGC led to the biosynthesis of an array of JAs in S. albus J1074, including JA A and possibly JA B or C. Whether the enzymatic activity required for MHB transfer to JA F has been provided in the heterologous DNA fragment (unlikely) or, on the contrary, is integrated in the host genome is unknown. Detection of additional JA derivatives in a heterologous host reinforces the idea that the biosynthetic machinery harbored in different actinobacteria lineages can be successfully combined and exploited to generate structural diversity.
Expression of the JA BGC seems to be regulated, as no JAs are detected in the heterologous host unless its biosynthesis is elicited by ermE*p insertion upstream of jomP1. Gene deletion and overexpression experiments have not demonstrated the direct involvement of putative transcriptional regulators coded in the surroundings of jomP1-jomM on JAs biosynthesis control. Hence, based on these results, presence of key regulators encoded outside the JAs BGC is foreseeable. Lack of essential gene functions in BGC is frequently explained on the basis of large-scale genetic rearrangements, such as inversions and transpositions, which are fundamental to genome evolution [67,68].
This work provides a first insight into the genetic bases of JAs biosynthesis and shows heterologous expression of BGCs as a suitable strategy to generate additional structural diversity. Moreover, availability of the JAs BGC enables further genetic manipulations aimed at generating novel derivatives with improved pharmacological properties and eases the elucidation of unraveled biosynthesis steps.

4. Materials and Methods

4.1. Strains, Tumor Cell Lines, Media and Cultivation Conditions

Streptomyces strains S. caniferus GUA-06-05-006A [69], S. coelicolor M1152 [70] and S. albus J1074 [36] were routinely maintained in medium A (MA) [71]. Metabolite production analyses and large scale fermentations in S.caniferus GUA-06-05-006A were performed in SMS medium as described elsewhere [44]. Heterologous production of JAs in S. coelicolor M1152 and S. albus J1074 was achieved after 3 days of cultivation at 30 °C in GYM [72] and R5A medium [71], respectively. Escherichia coli strains DH10B [73], used for cloning, ET12567/pUB307 [74] and ET12567/pUZ8002 [75], used for intergeneric conjugation, were grown in LB or 2× TY medium, supplemented with the appropriate antibiotic for plasmid selection [74].
Yeast strain Saccharomyces cerevisiae VL6-48 (MAT alpha, his3-D200, trp1-D1, ura3-52, lys2, ade2-101, met14, psi + cir0), used for TAR cloning, was grown in YPD or YNB-trp medium [76], made solid, when required, by addition of 2% agar.

4.2. DNA Manipulation

DNA manipulation in Escherichia coli and S. caniferus GUA-06-05-006A was carried out according to standard protocols [74,77]. Polymerase chain reaction (PCR) amplifications were performed by using Herculase II Fusion polymerase (Agilent Technologies, Palo Alto, CA, USA) with a previously reported touchdown PCR procedure [44]. All primers used in this work are described in Supplementary file 3: Table S1. Genetic manipulations in S. caniferus GUA-06-05-006A were confirmed by colony PCR by using the procedure described in [78] with the following modifications. Bacterial colonies were suspended in 50 μL of 0.2 M 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino] ethanesulfonic acid (TES) buffer, pH 7.5, with 1 μL lysozyme (50 mg/mL) and incubated for 40 min at 30 °C. The mix was centrifuged (10,000× g, 2 min) and the pellet thoroughly suspended in 10 μL dimethyl sulfoxide (DMSO). The resulting suspension (2 μL) was used as PCR template with the indicated primer pairs (Supplementary file 3: Table S1).

4.3. Plasmids Construction and Strain Generation

Information relevant to plasmids generated in this work is summarized in Supplementary file 3: Table S1. All plasmids were transferred to S.caniferus GUA-06-05-006Aby intergeneric conjugation as previously described [44]. For jomP1 and jomN insertional inactivation, internal gene fragments were amplified with the primer pairs EcoRI-P1/ HindIII-P1 and EcoRI-N/ HindIII-N, respectively, and cloned in the indicated restriction sites of plasmid pOJ260 [79], which lacks the capacity to replicate in Streptomyces and carries the aac(3)IV gene marker that confers resistance to apramycin(AmR). The resulting plasmids, pIjomP1 and pIjomN, were then transferred to S.caniferus GUA-06-05-006A to produce strains ∆jomP1 and ∆jomN, respectively. Insertion of ermE*p upstream of jomP1 was performed in the pOJ260 derivative pOJ260e as described in [36]. A 2.8 Kb fragment covering the jomP1 upstream region, including 108 bp from the start codon, was amplified with primers EcoRI-EP1/PstI-EP1 and cloned in pOJ260e to afford plasmid pEjomP1, which was used to generate strain G-permE*.
To accomplish single deletion of orf8, orf9, orf16, orf20, orf29, orf31 and jomM, the downstream DNA sequence of the referred target genes were amplified with the primer pairsBamHI-orf8/EcoRV-orf8, BglIIHI-orf9/EcoRV-orf9, BamHI-orf16/EcoRV-orf16, BamHI-orf20/EcoRV-orf20, BglIIHI-orf29/EcoRV-orf29, BglIIHI-orf31/EcoRV-orf31 and BglIIHI-M/EcoRV-M, respectively, and cloned in the designated restriction sites of plasmid pEFBA-oriT [80], downstream to the aac(3)IV gene. Then, the upstream sequence of the cited genes were likewise amplified with the primer pairs NsiI-orf8/SpeI-orf8, NsiI-orf9/SpeI-orf9, NsiI-orf16/SpeI-orf16, NsiI-orf20/SpeI-orf20, NsiI-orf29/SpeI-orf29, NsiI-orf31/SpeI-orf31 andNsiI-M/SpeI-M, respectively, and cloned upstream to the aac(3)IV gene. Finally, the hygromycin B resistance (HygR) gene marker, hyg, was extracted by XbaI/NheI digestion from plasmid pLHyg [81] and introduced in the XbaI site of the deletion plasmids. The resulting construction plasmids, pDorf8, pDorf9, pDorf16, pDorf20, pDorf29, pDorf31, pDjomM were introduced in S.caniferus GUA-06-05-006A to generate deletion strains ∆orf8-araC, ∆orf9, ∆orf16-luxR, ∆orf20-marR, ∆orf29-gntR, ∆orf31 and ∆jomM, respectively. Gene hyg allowed recognizing clones in which a complete gene replacement by a double cross-over has taken place (HygS AmR) from those in which a single cross-over event has integrated the deletion plasmid into the chromosome (HygR AmR).
A suitable plasmid backbone to accomplish ectopic expression was constructed as follows. A 930 bp fragment containing the kanamycin resistance marker aph(3) II was amplified from plasmid pCAP01 [37] with primers EcoRI-KanR/EcoRV-KanR and cloned in the integrative plasmid pSETec [82], contiguous to the constitutive ermE*p promoter to produce plasmid pSETk. Genes orf8, orf16, orf20, orf29 and jomM were amplified with primers indicated in Supplementary file 3: Table S1, and cloned in pSETk between ermE*p and aph(3) II. The resulting plasmids (Supplementary file 3: Table S1) were transferred to S.caniferus GUA-06-05-006A or ∆jomMto generate strains G-pSAraC, G-pSLuxR, G-pSMarR, G-pSGntR and ∆M-pSEJomM.

4.4. Heterologous Expression of the JAs BGC

The JAs BGC (orf9 to orf23) was captured by TAR cloning [37] for heterologous expression in S. coelicolor M1152 and S. albus J1074. Cluster capture arms of approximately 1 Kb were generated by PCR amplification with primer pairs XhoI-2TAR/NsiI-U2TAR and NsiI-L2TAR/SpeI-2TAR (Supplementary file 3: Table S1). PCR products were digested with NsiI and ligated. The resulting assembled fragment of 2 Kb was then amplified with primers XhoI-2TAR/SpeI-2TAR and cloned in the XhoI/SpeI sites of plasmid pCAP01 to afford the capture plasmid pCL2-CAP. Yeast strain Saccharomyces cerevisiae VL6-48 was then co-transformed [76] with pCL2-CAP (0.5 μg), linearized by digestion with NsiI, and S. caniferusGUA-06-05-006A genomic DNA (1 μg). Yeast transformants were selected on synthetic YNB–trp medium and screened by PCR for the presence of the JAs BGC. The resulting plasmid, p2NTAR, was extracted from three positive clones, subjected to physical characterization by BamHI, NcoI, NotI, PstI and EcoRV digestion and transferred to the heterologous Streptomyces hosts by intergeneric conjugation [44].
To produce plasmid pNTARe, the ermE*p promoter was integrated upstream of jomP1, in plasmid pJATAR, by ReDirect technology [83].The apramycin resistant gene marker aac(3)IV and ermE*p were amplified from plasmid pSETec [82] with the primer pairs dApra/NsiI-rvApra and dNsiI-pErm/rvpErm, respectively. The PCR products were digested with NsiI and ligated. The resulting aac(3)IV-ermE*p assembled fragment was then amplified with the primer pair dApra-pErm/rvApra-pErm to generate a DNA fragment flanked with suitable pJATAR homologous sequences to direct ermE*p integration upstream of jomP1. This fragment and pJATAR were introduced in E. coli BW25113 as described in [83]. Kanamycin/apramycin resistant transformants were selected and analyzed for correct ermE*p integration by sequencing with primers dNsiI-pErm, rvpErm, dApra and NsiI-rvApra.

4.5. Sequencing and Bioinformatics Analysis

The JAs BGC was identified and analyzed by the antibiotics and secondary metabolite analysis shell: antiSMASH 4.0 [84] and PRISM 3 [85,86]. Annotation of ORFs within the JA BGC was based on database searching of the corresponding proteins carried out by BLAST algorithm [87] at the National Center for Biotechnology Information (NCBI). Additional sequence alignments were conducted by Clustal Omega [88] and EMBOSS Water [89] from the European Molecular Biology Laboratory (EMBL).
The nucleotide sequence of the jomthonic acids biosynthesis gene cluster was deposited in the European Nucleotide Archive (accession number: LT990689) and at Minimum Information about a Biosynthetic Gene Cluster (MIBiG) repository [90] under the accession BGC0001457.

4.6. Analysis of Metabolite Production and Compound Purification

Whole culture samples (1 or 5 mL) were mixed with an equal volume of ethyl acetate and mixed on a rotary shaker at room temperature for 1 h. The organic phase was then recovered by centrifugation (3000× g, 10 min) and evaporated in vacuo. The resulting dry residue was dissolved in methanol:DMSO (1:1) to perform UPLC and LC-MS analyses as described elsewhere [91,92].
Compounds 1–3 were purified from 2.5 L of G-permE* culture supernatant. Culture was filtered and then applied to a solid-phase extraction cartridge (Sep-Pak Vac C18, 10 g, Waters, Mildford, MA, USA) that had been fitted with a perforated stopper pierced by a stainless steel HPLC (Waters, Mildford, MA, USA) tubing. The culture broth was applied by means of a peristaltic pump and subsequently the cartridge was connected to a HPLC quaternary pump (model 600E, Waters). The retained material was eluted with a mixture of methanol and 0.05% trifluoroacetic acid (TFA) in water. A linear gradient from 0 to 100% methanol in 60 min, at 10 mL/min, was used. Fractions were taken every 5 min, collected on 5 mL of 0.1 M phosphate buffer, pH 7.0 and analyzed by UPLC. Fractions containing the desired compounds were evaporated in vacuo and subsequently re-dissolved in a small volume of a DMSO:methanol (50:50) mixture. Compounds of interest were then purified by preparative HPLC using a SunFire C18 column (10 µm, 10 × 250 mm, Waters, Mildford, MA, USA). Organic extracts were chromatographed with mixtures of acetonitrile or methanol and 0.1% TFA in accurate isocratic conditions (7 mL/min), and collected on 0.1 M phosphate buffer (pH 7.0). After every purification step, the collected compounds were diluted 4-fold with water and then applied to a solid-phase extraction cartridge (Sep-Pak C18, Waters, Mildford, MA, USA). The cartridges were washed with water and compounds were eluted with methanol and dried in vacuo. Once the purification was finished, the compounds were dissolved in a mixture of tert-butanol and water (1:1) and lyophilized, obtaining 21.9, 3.8 and 3.9 mg of compounds 1, 2 and 3, respectively.

4.7. Mass Spectra and Structural Elucidation

NMR spectra were obtained on a Varian “Unity 500” spectrometer (Agilent Technologies, Palo Alto, CA, USA) at 500/125 MHz (1H/13C) and on a Varian “Unity 400” spectrometer (Agilent Technologies, Palo Alto, CA, USA) at 400/100 MHz (1H/13C). Chemical shifts were reported in ppm using residual CDCl3 (δ 7.26 ppm for 1H and 77.0 ppm for 13C) as an internal reference. COSY, HSQC and HMBC experiments were performed using standard pulse sequences. Data were processed using MestReNova software (Mnova, Santiago de Compostela, Spain). (+)ESIMS were recorded using an Agilent 1100 Series LC/MS spectrometer (Agilent Technologies, Palo Alto, CA, USA). High resolution mass spectroscopy (HRMS) was performed on an Agilent 6230 TOF LC/MS system (Agilent Technologies, Palo Alto, CA, USA) using the electrospray ionization mass spectrometry (ESI-MS) technique.

Supplementary Materials

The following are available online at https://www.mdpi.com/1660-3397/16/8/259/s1, Supplementary file 1: Figure S1–S21, Supplementary file 2: Figure S22–S26, Supplementary file 3: Table S1 and Figure S27.

Author Contributions

J.A.S.; C.O.; C.M.; F.d.l.C. and R.G.-S. conceived and designed the study. R.G.-S. and R.Á.Á. conducted experiments. C.O. carried out in sillico analyses. A.F.B. performed compound purifications. L.C. elucidated chemical structures. R.G.-S. wrote the manuscript and all authors contributed to edit and critically review the paper.

Funding

This research was funded by grants of the Spanish Ministry of Economy and Competitiveness INNPACTO IPT-2011-0752-900000 to J.A.S and F.d.l.C, BIO2015-64161-R to J.A.S and “Apoyo a grupos de excelencia” Principado de Asturias-FEDER (FC-15-GRUPIN14-014) to J.A.S.

Acknowledgments

The authors wish to thank Fundación BancariaCajastur for financial support to C.O.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Waters, A.L.; Hill, R.T.; Place, A.R.; Hamann, M.T. The expanding role of marine microbes in pharmaceutical development. Curr. Opin. Biotechnol. 2010, 21, 780–786. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Snelgrove, P.V.R. An Ocean of Discovery: Biodiversity Beyond the Census of Marine Life. Planta Med. 2016, 82, 790–799. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Williams, J.A.; Day, M.; Heavner, J.E. Ziconotide: An update and review. Expert Opin. Pharmacother. 2008, 9, 1575–1583. [Google Scholar] [CrossRef] [PubMed]
  4. Yasuhara-Bell, J.; Lu, Y. Marine compounds and their antiviral activities. Antiviral Res. 2010, 86, 231–240. [Google Scholar] [CrossRef] [PubMed]
  5. Cuevas, C.; Francesch, A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat. Prod. Rep. 2009, 26, 322–337. [Google Scholar] [CrossRef] [PubMed]
  6. Stonik, V.A. Marine natural products: a way to new drugs. Acta Nat. 2009, 1, 15–25. [Google Scholar]
  7. Anjum, K.; Abbas, S.Q.; Akhter, N.; Shagufta, B.I.; Shah, S.A.A.; Hassan, S.S.U. Emerging biopharmaceuticals from bioactive peptides derived from marine organisms. Chem. Biol. Drug Des. 2017, 90, 12–30. [Google Scholar] [CrossRef] [PubMed]
  8. Sipkema, D.; Franssen, M.C.R.; Osinga, R.; Tramper, J.; Wijffels, R.H. Marine sponges as pharmacy. Mar. Biotechnol. (N.Y.) 2005, 7, 142–162. [Google Scholar] [CrossRef] [PubMed]
  9. Anjum, K.; Abbas, S.Q.; Shah, S.A.A.; Akhter, N.; Batool, S.; Hassan, S.S. ul Marine Sponges as a Drug Treasure. Biomol. Ther. (Seoul) 2016, 24, 347–362. [Google Scholar] [CrossRef] [PubMed]
  10. Bernan, V.S.; Greenstein, M.; Maiese, W.M. Marine microorganisms as a source of new natural products. Adv. Appl. Microbiol. 1997, 43, 57–90. [Google Scholar] [PubMed]
  11. Simmons, T.L.; Coates, R.C.; Clark, B.R.; Engene, N.; Gonzalez, D.; Esquenazi, E.; Dorrestein, P.C.; Gerwick, W.H. Biosynthetic origin of natural products isolated from marine microorganism-invertebrate assemblages. Proc. Natl. Acad. Sci. USA 2008, 105, 4587–4594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Romano, G.; Costantini, M.; Sansone, C.; Lauritano, C.; Ruocco, N.; Ianora, A. Marine microorganisms as a promising and sustainable source of bioactive molecules. Mar. Environ. Res. 2017, 128, 58–69. [Google Scholar] [CrossRef] [PubMed]
  13. Sarmiento-Vizcaíno, A.; González, V.; Braña, A.F.; Palacios, J.J.; Otero, L.; Fernández, J.; Molina, A.; Kulik, A.; Vázquez, F.; Acuña, J.L.; et al. Pharmacological Potential of Phylogenetically Diverse Actinobacteria Isolated from Deep-Sea Coral Ecosystems of the Submarine Avilés Canyon in the Cantabrian Sea. Microb. Ecol. 2017, 73, 338–352. [Google Scholar] [CrossRef] [PubMed]
  14. Brady, S.F.; Simmons, L.; Kim, J.H.; Schmidt, E.W. Metagenomic approaches to natural products from free-living and symbiotic organisms. Nat. Prod. Rep. 2009, 26, 1488. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Heidelberg, K.B.; Gilbert, J.A.; Joint, I. Marine genomics: At the interface of marine microbial ecology and biodiscovery. Microb. Biotechnol. 2010, 3, 531–543. [Google Scholar] [CrossRef] [PubMed]
  16. Mühling, M.; Joint, I.; Willetts, A.J. The biodiscovery potential of marine bacteria: An investigation of phylogeny and function. Microb. Biotechnol. 2013, 6, 361–370. [Google Scholar] [CrossRef] [PubMed]
  17. Amoutzias, G.; Chaliotis, A.; Mossialos, D. Discovery Strategies of Bioactive Compounds Synthesized by Nonribosomal Peptide Synthetases and Type-I Polyketide Synthases Derived from Marine Microbiomes. Mar. Drugs 2016, 14, 80. [Google Scholar] [CrossRef] [PubMed]
  18. Singh, M.; Chaudhary, S.; Sareen, D. Non-ribosomal peptide synthetases: Identifying the cryptic gene clusters and decoding the natural product. J. Biosci. 2017, 42, 175–187. [Google Scholar] [CrossRef] [PubMed]
  19. Tseng, C.-H.; Tang, S.-L. Marine Microbial Metagenomics: From Individual to the Environment. Int. J. Mol. Sci. 2014, 15, 8878–8892. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Uchiyama, I.; Mihara, M.; Nishide, H.; Chiba, H. MBGD update 2015: Microbial genome database for flexible ortholog analysis utilizing a diverse set of genomic data. Nucleic Acids Res. 2015, 43, D270–D276. [Google Scholar] [CrossRef] [PubMed]
  21. Haroon, M.F.; Thompson, L.R.; Parks, D.H.; Hugenholtz, P.; Stingl, U. A catalogue of 136 microbial draft genomes from Red Sea metagenomes. Sci. Data 2016, 3, 160050. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Katz, L.; Baltz, R.H. Natural product discovery: Past, present, and future. J. Ind. Microbiol. Biotechnol. 2016, 43, 155–176. [Google Scholar] [CrossRef] [PubMed]
  23. Jensen, P.R. Natural Products and the Gene Cluster Revolution. Trends Microbiol. 2016, 24, 968–977. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Niu, G. Genomics-Driven Natural Product Discovery in Actinomycetes. Trends Biotechnol. 2018, 36, 238–241. [Google Scholar] [CrossRef] [PubMed]
  25. Challis, G.L. Mining microbial genomes for new natural products and biosynthetic pathways. Microbiology 2008, 154, 1555–1569. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. McAlpine, J.B. Advances in the understanding and use of the genomic base of microbial secondary metabolite biosynthesis for the discovery of new natural products. J. Nat. Prod. 2009, 72, 566–572. [Google Scholar] [CrossRef] [PubMed]
  27. Nett, M.; Ikeda, H.; Moore, B.S. Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat. Prod. Rep. 2009, 26, 1362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Li, J.W.-H.; Vederas, J.C. Drug Discovery and Natural Products: End of an Era or an Endless Frontier? Science 2009, 325, 161–165. [Google Scholar] [CrossRef] [PubMed]
  29. Abdelmohsen, U.R.; Grkovic, T.; Balasubramanian, S.; Kamel, M.S.; Quinn, R.J.; Hentschel, U. Elicitation of secondary metabolism in actinomycetes. Biotechnol. Adv. 2015, 33, 798–811. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Reen, F.J.; Romano, S.; Dobson, A.D.W.; O’Gara, F. The Sound of Silence: Activating Silent Biosynthetic Gene Clusters in Marine Microorganisms. Mar. Drugs 2015, 13, 4754–4783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Baltz, R.H. Genetic manipulation of secondary metabolite biosynthesis for improved production in Streptomyces and other actinomycetes. J. Ind. Microbiol. Biotechnol. 2016, 43, 343–370. [Google Scholar] [CrossRef] [PubMed]
  32. Ochi, K. Insights into microbial cryptic gene activation and strain improvement: Principle, application and technical aspects. J. Antibiot. (Tokyo) 2017, 70, 25–40. [Google Scholar] [CrossRef] [PubMed]
  33. Jensen, P.R.; Chavarria, K.L.; Fenical, W.; Moore, B.S.; Ziemert, N. Challenges and triumphs to genomics-based natural product discovery. J. Ind. Microbiol. Biotechnol. 2014, 41, 203–209. [Google Scholar] [CrossRef] [PubMed]
  34. Gomez-Escribano, J.; Alt, S.; Bibb, M. Next Generation Sequencing of Actinobacteria for the Discovery of Novel Natural Products. Mar. Drugs 2016, 14, 78. [Google Scholar] [CrossRef] [PubMed]
  35. Luo, Y.; Huang, H.; Liang, J.; Wang, M.; Lu, L.; Shao, Z.; Cobb, R.E.; Zhao, H. Activation and characterization of a cryptic polycyclic tetramate macrolactam biosynthetic gene cluster. Nat. Commun. 2013, 4, 2894. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Olano, C.; García, I.; González, A.; Rodriguez, M.; Rozas, D.; Rubio, J.; Sánchez-Hidalgo, M.; Braña, A.F.; Méndez, C.; Salas, J.A. Activation and identification of five clusters for secondary metabolites in Streptomyces albus J1074. Microb. Biotechnol. 2014, 7, 242–256. [Google Scholar] [CrossRef] [PubMed]
  37. Yamanaka, K.; Reynolds, K.A.; Kersten, R.D.; Ryan, K.S.; Gonzalez, D.J.; Nizet, V.; Dorrestein, P.C.; Moore, B.S. Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster yields the antibiotic taromycin A. Proc. Natl. Acad. Sci. USA 2014, 1–6. [Google Scholar] [CrossRef] [PubMed]
  38. Saha, S.; Zhang, W.; Zhang, G.; Zhu, Y.; Chen, Y.; Liu, W.; Yuan, C.; Zhang, Q.; Zhang, H.; Zhang, L.; et al. Activation and characterization of a cryptic gene cluster reveals a cyclization cascade for polycyclic tetramate macrolactams. Chem. Sci. 2017, 8, 1607–1612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Frattaruolo, L.; Lacret, R.; Cappello, A.R.; Truman, A.W. A Genomics-Based Approach Identifies a Thioviridamide-Like Compound with Selective Anticancer Activity. ACS Chem. Biol. 2017, 12, 2815–2822. [Google Scholar] [CrossRef] [PubMed]
  40. Xu, J.; Zhang, J.; Zhuo, J.; Li, Y.; Tian, Y.; Tan, H. Activation and mechanism of a cryptic oviedomycin gene cluster via the disruption of a global regulatory gene, adpA, in Streptomyces ansochromogenes. J. Biol. Chem. 2017, 292, 19708–19720. [Google Scholar] [CrossRef] [PubMed]
  41. Kawahara, T.; Izumikawa, M.; Kozone, I.; Hashimoto, J.; Kagaya, N.; Koiwai, H.; Komatsu, M.; Fujie, M.; Sato, N.; Ikeda, H.; et al. Neothioviridamide, a Polythioamide Compound Produced by Heterologous Expression of a Streptomyces sp. Cryptic RiPP Biosynthetic Gene Cluster. J. Nat. Prod. 2018, 81, 264–269. [Google Scholar] [CrossRef] [PubMed]
  42. Igarashi, Y.; Yu, L.; Ikeda, M.; Oikawa, T.; Kitani, S.; Nihira, T.; Bayanmunkh, B.; Panbangred, W. Jomthonic acid A, a modified amino acid from a soil-derived Streptomyces. J. Nat. Prod. 2012, 75, 986–990. [Google Scholar] [CrossRef] [PubMed]
  43. Yu, L.; Oikawa, T.; Kitani, S.; Nihira, T.; Bayanmunkh, B.; Panbangred, W.; Igarashi, Y. Jomthonic acids B and C, two new modified amino acids from Streptomyces sp. J. Antibiot. (Tokyo) 2014, 67, 345–347. [Google Scholar] [CrossRef] [PubMed]
  44. Salcedo, R.G.; Olano, C.; Gómez, C.; Fernández, R.; Braña, A.F.; Méndez, C.; de la Calle, F.; Salas, J.A. Characterization and engineering of the biosynthesis gene cluster for antitumor macrolides PM100117 and PM100118 from a marine actinobacteria: Generation of a novel improved derivative. Microb. Cell Fact. 2016, 15, 44. [Google Scholar] [CrossRef] [PubMed]
  45. Magarvey, N.A.; Haltli, B.; He, M.; Greenstein, M.; Hucul, J.A. Biosynthetic pathway for mannopeptimycins, lipoglycopeptide antibiotics active against drug-resistant gram-positive pathogens. Antimicrob. Agents Chemother. 2006, 50, 2167–2177. [Google Scholar] [CrossRef] [PubMed]
  46. Gaitatzis, N.; Silakowski, B.; Kunze, B.; Nordsiek, G.; Blöcker, H.; Höfle, G.; Müller, R. The biosynthesis of the aromatic myxobacterial electron transport inhibitor stigmatellin is directed by a novel type of modular polyketide synthase. J. Biol. Chem. 2002, 277, 13082–13090. [Google Scholar] [CrossRef] [PubMed]
  47. Silakowski, B.; Schairer, H.U.; Ehret, H.; Kunze, B.; Weinig, S.; Nordsiek, G.; Brandt, P.; Blöcker, H.; Höfle, G.; Beyer, S.; et al. New lessons for combinatorial biosynthesis from myxobacteria. The myxothiazol biosynthetic gene cluster of Stigmatella aurantiaca DW4/3-1. J. Biol. Chem. 1999, 274, 37391–37399. [Google Scholar] [CrossRef] [PubMed]
  48. Silakowski, B.; Nordsiek, G.; Kunze, B.; Blöcker, H.; Müller, R. Novel features in a combined polyketide synthase/non-ribosomal peptide synthetase: The myxalamid biosynthetic gene cluster of the myxobacterium Stigmatella aurantiaca Sga15. Chem. Biol. 2001, 8, 59–69. [Google Scholar] [CrossRef]
  49. Ligon, J.; Hill, S.; Beck, J.; Zirkle, R.; Molnár, I.; Zawodny, J.; Money, S.; Schupp, T. Characterization of the biosynthetic gene cluster for the antifungal polyketide soraphen A from Sorangium cellulosum So ce26. Gene 2002, 285, 257–267. [Google Scholar] [CrossRef]
  50. Petković, H.; Sandmann, A.; Challis, I.R.; Hecht, H.-J.; Silakowski, B.; Low, L.; Beeston, N.; Kuščer, E.; Garcia-Bernardo, J.; Leadlay, P.F.; et al. Substrate specificity of the acyl transferase domains of EpoC from the epothilone polyketide synthase. Org. Biomol. Chem. 2008, 6, 500–506. [Google Scholar] [CrossRef] [PubMed]
  51. Liew, C.W.; Nilsson, M.; Chen, M.W.; Sun, H.; Cornvik, T.; Liang, Z.-X.; Lescar, J. Crystal structure of the acyltransferase domain of the iterative polyketide synthase in enediyne biosynthesis. J. Biol. Chem. 2012, 287, 23203–23215. [Google Scholar] [CrossRef] [PubMed]
  52. Huang, Y.-T.; Lyu, S.-Y.; Chuang, P.-H.; Hsu, N.-S.; Li, Y.-S.; Chan, H.-C.; Huang, C.-J.; Liu, Y.-C.; Wu, C.-J.; Yang, W.-B.; et al. In vitro characterization of enzymes involved in the synthesis of nonproteinogenic residue (2S,3S)-beta-methylphenylalanine in glycopeptide antibiotic mannopeptimycin. ChemBiochem 2009, 10, 2480–2487. [Google Scholar] [CrossRef] [PubMed]
  53. Wu, W.M.; Jain, M.K.; Zeikus, J.G. Anaerobic degradation of normal- and branched-chain Fatty acids with four or more carbons to methane by a syntrophic methanogenic triculture. Appl. Environ. Microbiol. 1994, 60, 2220–2226. [Google Scholar] [PubMed]
  54. Narihiro, T.; Nobu, M.K.; Tamaki, H.; Kamagata, Y.; Sekiguchi, Y.; Liu, W.-T. Comparative Genomics of Syntrophic Branched-Chain Fatty Acid Degrading Bacteria. Microbes Environ. 2016, 31, 288–292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Felnagle, E.A.; Barkei, J.J.; Park, H.; Podevels, A.M.; McMahon, M.D.; Drott, D.W.; Thomas, M.G. MbtH-like proteins as integral components of bacterial nonribosomal peptide synthetases. Biochemistry 2010, 49, 8815–8817. [Google Scholar] [CrossRef] [PubMed]
  56. Zolova, O.E.; Garneau-Tsodikova, S. Importance of the MbtH-like protein TioT for production and activation of the thiocoraline adenylation domain of TioK. Medchemcomm 2012, 3, 950. [Google Scholar] [CrossRef]
  57. Camp, H.S.; Ren, D.; Leff, T. Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol. Med. 2002, 8, 442–447. [Google Scholar] [CrossRef]
  58. Kassotis, C.D.; Masse, L.; Kim, S.; Schlezinger, J.J.; Webster, T.F.; Stapleton, H.M. Characterization of Adipogenic Chemicals in Three Different Cell Culture Systems: Implications for Reproducibility Based on Cell Source and Handling. Sci. Rep. 2017, 7, 42104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Calabro, P.; Yeh, E.T. Obesity, inflammation, and vascular disease: The role of the adipose tissue as an endocrine organ. Subcell. Biochem. 2007, 42, 63–91. [Google Scholar] [PubMed]
  60. Moore, B.S.; Trischman, J.A.; Seng, D.; Kho, D.; Jensen, P.R.; Fenical, W. Salinamides, antiinflammatory depsipeptides from a marine streptomycete. J. Org. Chem. 1999, 64, 1145–1150. [Google Scholar] [CrossRef]
  61. Quang, D.N.; Hashimoto, T.; Tanaka, M.; Stadler, M.; Asakawa, Y. Cyclic azaphilones daldinins E and F from the ascomycete fungus Hypoxylon fuscum (Xylariaceae). Phytochemistry 2004, 65, 469–473. [Google Scholar] [CrossRef] [PubMed]
  62. Houge-Frydrych, C.S.; Gilpin, M.L.; Skett, P.W.; Tyler, J.W. SB-203207 and SB-203208, two novel isoleucyl tRNA synthetase inhibitors from a Streptomyces sp. II. Structure determination. J. Antibiot. (Tokyo) 2000, 53, 364–372. [Google Scholar] [CrossRef] [PubMed]
  63. Yamada, T.; Yagita, M.; Kobayashi, Y.; Sennari, G.; Shimamura, H.; Matsui, H.; Horimatsu, Y.; Hanaki, H.; Hirose, T.; Omura, S.; et al. Synthesis and Evaluation of Antibacterial Activity of Bottromycins. J. Org. Chem. 2018, 83, 7135–7149. [Google Scholar] [CrossRef] [PubMed]
  64. Takaoka, S.; Kurata, M.; Harimoto, Y.; Hatta, R.; Yamamoto, M.; Akimitsu, K.; Tsuge, T. Complex regulation of secondary metabolism controlling pathogenicity in the phytopathogenic fungus Alternaria alternata. New Phytol. 2014, 202, 1297–1309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Rössner, E.; Zeeck, A.; König, W.A. Elucidation of the Structure of Hormaomycin. Angew. Chem. Int. Ed. Engl. 1990, 29, 64–65. [Google Scholar] [CrossRef]
  66. Fuse, S.; Koinuma, H.; Kimbara, A.; Izumikawa, M.; Mifune, Y.; He, H.; Shin-ya, K.; Takahashi, T.; Doi, T. Total synthesis and stereochemistry revision of mannopeptimycin aglycone. J. Am. Chem. Soc. 2014, 136, 12011–12017. [Google Scholar] [CrossRef] [PubMed]
  67. Dandekar, T.; Snel, B.; Huynen, M.; Bork, P. Conservation of gene order: A fingerprint of proteins that physically interact. Trends Biochem. Sci. 1998, 23, 324–328. [Google Scholar] [CrossRef]
  68. Ochman, H.; Moran, N.A. Genes lost and genes found: Evolution of bacterial pathogenesis and symbiosis. Science 2001, 292, 1096–1099. [Google Scholar] [CrossRef] [PubMed]
  69. Pérez, M.; Schleissner, C.; Fernández, R.; Rodríguez, P.; Reyes, F.; Zuñiga, P.; de la Calle, F.; Cuevas, C. PM100117 and PM100118, new antitumor macrolides produced by a marine Streptomyces caniferus GUA-06-05-006A. J. Antibiot. (Tokyo) 2015, 1–7. [Google Scholar] [CrossRef] [PubMed]
  70. Gomez-Escribano, J.P.; Bibb, M.J. Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters. Microb. Biotechnol. 2011, 4, 207–215. [Google Scholar] [CrossRef] [PubMed]
  71. Fernández, E.; Weissbach, U.; Sánchez Reillo, C.; Braña, A.F.; Méndez, C.; Rohr, J.; Salas, J.A. Identification of two genes from Streptomyces argillaceus encoding glycosyltransferases involved in transfer of a disaccharide during biosynthesis of the antitumor drug mithramycin. J. Bacteriol. 1998, 180, 4929–4937. [Google Scholar] [PubMed]
  72. Hu, H.; Zhang, Q.; Ochi, K. Activation of antibiotic biosynthesis by specified mutations in the rpoB gene (encoding the RNA polymerase beta subunit) of Streptomyces lividans. J. Bacteriol. 2002, 184, 3984–3991. [Google Scholar] [CrossRef] [PubMed]
  73. Grant, S.G.N.; Jessee, J.; Bloom, F.R.; Hanahan, D. Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylation-restriction mutants. Proc. Natl. Acad. Sci. USA 1990, 87, 4645–4649. [Google Scholar] [CrossRef] [PubMed]
  74. Kieser, T.; Bibb, M.J.; Buttner, M.J.; Chater, K.F.; Hopwood, D. Practical Streptomyces Genetics; The John Innes Centre: Norwich, UK, 2000; ISBN 0708406238. [Google Scholar]
  75. Strain C5 Paranthaman, S.; Dharmalingam, K. Intergeneric conjugation in streptomyces peucetius and streptomyces sp. Strain C5: Chromosomal Integration and Expression of Recombinant Plasmids Carrying the chiC Gene. Appl. Environ. Microbiol. 2003, 69, 84–91. [Google Scholar] [CrossRef] [PubMed]
  76. Gietz, R.D. Yeast Transformation by the LiAc/SS Carrier DNA/PEG Method. In Methods in Molecular Biology (Clifton, N.J.); Springer Nature Switzerland AG: Basel, Switzerland, 2014; Volume 1205, pp. 1–12. [Google Scholar]
  77. Sambrook, J.; Russell, D.W. Molecular Cloning: A. Laboratory Manual; Cold Spring Harbor Laboratory: New York, NY, USA, 2001. [Google Scholar]
  78. Van Dessel, W.; Van Mellaert, L.; Geukens, N.; Anné, J. Improved PCR-based method for the direct screening of Streptomyces transformants. J. Microbiol. Methods 2003, 53, 401–403. [Google Scholar] [CrossRef]
  79. Bierman, M.; Logan, R.; O’Brien, K.; Seno, E.T.; Rao, R.N.; Schoner, B.E. Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp. Gene 1992, 116, 43–49. [Google Scholar] [CrossRef]
  80. Horna, D.H.; Gómez, C.; Olano, C.; Palomino-Schätzlein, M.; Pineda-Lucena, A.; Carbajo, R.J.; Braña, A.F.; Méndez, C.; Salas, J.A. Biosynthesis of the RNA polymerase inhibitor streptolydigin in Streptomyces lydicus: Tailoring modification of 3-methyl-aspartate. J. Bacteriol. 2011, 193, 2647–2651. [Google Scholar] [CrossRef] [PubMed]
  81. Olano, C.; Moss, S.J.; Braña, A.F.; Sheridan, R.M.; Math, V.; Weston, A.J.; Méndez, C.; Leadlay, P.F.; Wilkinson, B.; Salas, J.A. Biosynthesis of the angiogenesis inhibitor borrelidin by Streptomyces parvulus Tü4055: Insights into nitrile formation. Mol. Microbiol. 2004, 52, 1745–1756. [Google Scholar] [CrossRef] [PubMed]
  82. Cano-Prieto, C.; García-Salcedo, R.; Sánchez-Hidalgo, M.; Braña, A.F.; Fiedler, H.-P.; Méndez, C.; Salas, J.A.; Olano, C. Genome Mining of Streptomyces sp. Tü 6176: Characterization of the Nataxazole Biosynthesis Pathway. ChemBioChem 2015, 16, 1461–1473. [Google Scholar] [CrossRef] [PubMed]
  83. Gust, B.; Kieser, T.; Chater, K. Redirect Technology: PCR Targeting System in Streptomyces Coelicolor; The John Innes Centre: Norwich, UK, 2002. [Google Scholar]
  84. Blin, K.; Wolf, T.; Chevrette, M.G.; Lu, X.; Schwalen, C.J.; Kautsar, S.A.; Suarez Duran, H.G.; de Los Santos, E.L.C.; Kim, H.U.; Nave, M.; et al. Antismash 4.0-improvements in chemistry prediction and gene cluster boundary identification. Nucleic Acids Res. 2017, 45, W36–W41. [Google Scholar] [CrossRef] [PubMed]
  85. Skinnider, M.A.; Johnston, C.W.; Edgar, R.E.; Dejong, C.A.; Merwin, N.J.; Rees, P.N.; Magarvey, N.A. Genomic charting of ribosomally synthesized natural product chemical space facilitates targeted mining. Proc. Natl. Acad. Sci. USA 2016, 113, E6343–E6351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Skinnider, M.A.; Dejong, C.A.; Rees, P.N.; Johnston, C.W.; Li, H.; Webster, A.L.H.; Wyatt, M.A.; Magarvey, N.A. Genomes to natural products PRediction Informatics for Secondary Metabolomes (PRISM). Nucleic Acids Res. 2015, 43, 9645–9662. [Google Scholar] [CrossRef] [PubMed]
  87. Altschul, S.F.; Madden, T.L.; Schäffer, A.A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D.J. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 1997, 25, 3389–3402. [Google Scholar] [CrossRef] [PubMed]
  88. Sievers, F.; Higgins, D.G. Clustal Omega, Accurate Alignment of Very Large Numbers of Sequences. In Methods in Molecular Biology (Clifton, N.J.); Springer Nature Switzerland AG: Basel, Switzerland, 2014; Volume 1079, pp. 105–116. [Google Scholar]
  89. Rice, P.; Longden, I.; Bleasby, A. EMBOSS: The European Molecular Biology Open Software Suite. Trends Genet. 2000, 16, 276–277. [Google Scholar] [CrossRef]
  90. Medema, M.H.; Kottmann, R.; Yilmaz, P.; Cummings, M.; Biggins, J.B.; Blin, K.; de Bruijn, I.; Chooi, Y.H.; Claesen, J.; Coates, R.C.; et al. Minimum Information about a Biosynthetic Gene cluster. Nat. Chem. Biol. 2015, 11, 625–631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  91. Losada, A.A.; Cano-Prieto, C.; García-Salcedo, R.; Braña, A.F.; Méndez, C.; Salas, J.A.; Olano, C. Caboxamycin biosynthesis pathway and identification of novel benzoxazoles produced by cross-talk in Streptomyces sp. NTK 937. Microb. Biotechnol. 2017, 10, 873–885. [Google Scholar] [CrossRef] [PubMed]
  92. Schleissner, C.; Cañedo, L.M.; Rodríguez, P.; Crespo, C.; Zúñiga, P.; Peñalver, A.; de la Calle, F.; Cuevas, C. Bacterial Production of a Pederin Analogue by a Free-Living Marine Alphaproteobacterium. J. Nat. Prod. 2017, 80, 2170–2173. [Google Scholar] [CrossRef] [PubMed]
Marinedrugs 16 00259 g001 550
Figure 1. Organization of the jomthonic acids biosynthetic gene cluster. The proposed gene functions are listed in Table 1. Grey bar indicates DNA fragment cloned in plasmid pJATAR for heterologous expression.
Figure 1. Organization of the jomthonic acids biosynthetic gene cluster. The proposed gene functions are listed in Table 1. Grey bar indicates DNA fragment cloned in plasmid pJATAR for heterologous expression.
Marinedrugs 16 00259 g001
Marinedrugs 16 00259 g002 550
Figure 2. Activation of jomthonic acids biosynthesis. (A) Metabolite analysis by UPLC of Streptomyces caniferus GUA-06-05-006A (wild type), G-perm*strain (constitutive promoter ermE*p inserted) and mutants ΔjomP1 and ΔjomN. Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated. (B) Chemical structures of jomthonic acid A and novel derivatives D and E. Asterisks indicate structural differences among the three compounds.
Figure 2. Activation of jomthonic acids biosynthesis. (A) Metabolite analysis by UPLC of Streptomyces caniferus GUA-06-05-006A (wild type), G-perm*strain (constitutive promoter ermE*p inserted) and mutants ΔjomP1 and ΔjomN. Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated. (B) Chemical structures of jomthonic acid A and novel derivatives D and E. Asterisks indicate structural differences among the three compounds.
Marinedrugs 16 00259 g002
Marinedrugs 16 00259 g003 550
Figure 3. Proposed biosynthesis pathway of jomthonic acids. Polyketide synthase (JomP1 and JomP2) and non-ribosomal protein synthetase (JomN) domains are as follows: KS ketosynthase, AT acyltransferase, KR ketoreductase, DH dehydratase, ACP acyl-carrier-protein, C condensation, Aadenylation, PCP peptidyl carrier protein. Compounds not detected in S. caniferus GUA-06-05-006A are shown in grey. Parentheses indicate structures not confirmed by NMR. Genes coding for enzymes X1, X2 and X3 were not identified in the biosynthesis gene cluster.
Figure 3. Proposed biosynthesis pathway of jomthonic acids. Polyketide synthase (JomP1 and JomP2) and non-ribosomal protein synthetase (JomN) domains are as follows: KS ketosynthase, AT acyltransferase, KR ketoreductase, DH dehydratase, ACP acyl-carrier-protein, C condensation, Aadenylation, PCP peptidyl carrier protein. Compounds not detected in S. caniferus GUA-06-05-006A are shown in grey. Parentheses indicate structures not confirmed by NMR. Genes coding for enzymes X1, X2 and X3 were not identified in the biosynthesis gene cluster.
Marinedrugs 16 00259 g003
Marinedrugs 16 00259 g004 550
Figure 4. Deletion of jomM and genes potentially involved in JA D and E biosynthesis. UPLC analysis of jomthonic acids biosynthesis in Streptomyces caniferus GUA-06-05-006A (wild type) and mutant strains ∆orf31, ∆orf9 and ∆jomM. Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated.
Figure 4. Deletion of jomM and genes potentially involved in JA D and E biosynthesis. UPLC analysis of jomthonic acids biosynthesis in Streptomyces caniferus GUA-06-05-006A (wild type) and mutant strains ∆orf31, ∆orf9 and ∆jomM. Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated.
Marinedrugs 16 00259 g004
Marinedrugs 16 00259 g005 550
Figure 5. Cluster boundaries analysis. UPLC analysis of jomthonic acids production in (A) Streptomyces caniferus GUA-06-05-006A (wild type) and mutant strains ∆orf29-gntR, ∆orf20-marR, ∆orf16-luxR and ∆orf8-araC, and (B) Streptomyces caniferus GUA-06-05-006A carrying overexpression plasmids pSETk (empty plasmid), pSEGntR (orf29), pSEMarR (orf20), pSESARP (orf16) and pSEAraC (orf8). Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated.
Figure 5. Cluster boundaries analysis. UPLC analysis of jomthonic acids production in (A) Streptomyces caniferus GUA-06-05-006A (wild type) and mutant strains ∆orf29-gntR, ∆orf20-marR, ∆orf16-luxR and ∆orf8-araC, and (B) Streptomyces caniferus GUA-06-05-006A carrying overexpression plasmids pSETk (empty plasmid), pSEGntR (orf29), pSEMarR (orf20), pSESARP (orf16) and pSEAraC (orf8). Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated.
Marinedrugs 16 00259 g005
Marinedrugs 16 00259 g006 550
Figure 6. Heterologous expression of the jomthonic acids biosynthesis gene cluster. UPLC metabolite analysis of (A) Streptomyces coelicolor M1152 and (B) Streptomyces albus J1074 carrying plasmid pCAP01 (empty plasmid), pJATAR (JAs BGC) and pJATARe (JAs BGC with ermE*pinserted). (C) Speculative chemical structure of peaks 2a (jomthonic acids B or C) in S. albus J1074.
Figure 6. Heterologous expression of the jomthonic acids biosynthesis gene cluster. UPLC metabolite analysis of (A) Streptomyces coelicolor M1152 and (B) Streptomyces albus J1074 carrying plasmid pCAP01 (empty plasmid), pJATAR (JAs BGC) and pJATARe (JAs BGC with ermE*pinserted). (C) Speculative chemical structure of peaks 2a (jomthonic acids B or C) in S. albus J1074.
Marinedrugs 16 00259 g006
Table
Table 1. Deduced functions of open reading frames (ORFs) in jomthonic acids biosynthetic gene cluster.
Table 1. Deduced functions of open reading frames (ORFs) in jomthonic acids biosynthetic gene cluster.
GeneDeduced aa. LengthProtein Homologue (Accession No.)Identity/Similarity (%)Proposed Function
orf1194WP_030077520.193/86RNA polymerase
orf2313WP_053208602.195/96Hypothetical protein
orf31462WP_084771961.194/96Cell division protein FtsK
orf41525WP_055485092.159/70Type IV secretion protein Rhs
orf5241WP_084771964.193/95Hypothetical protein
orf6104WP_084771965.186/94Hypothetical protein
orf799WP_033268020.199/100WXG-like protein
orf8289SDQ83237.189/91AraC-family transcriptional regulator
orf9396SDQ83203.187/93Monooxygenase
orf10315OSY47464.192/94FG-GAP repeat protein
orf1195OSY47461.196/96Type II toxin–antitoxin system
orf12286OSY47460.191/94Thioesterase
orf13218WP_085923163.199/99ATP-dependent Clp protease proteolytic subunit
orf14106OSY47458.195/97Hypothetical protein
orf15 --Unassigned
jomP12093WP_020735335.147/58Type I polyketide synthase (PCP/KS/AT/AT/KR/PCP)
jomP21853CAD19087.143/57Type I polyketide synthase (KS/AT/DH/KR/PCP)
jomN1062SCL52665.148/63Non-ribosomal protein synthetase(C/A/PCP)
jomT254WP_025675064.135/51Thioesterase
jomB72WP_004933768.172/83mbtH-like protein
jomM329WP_004933770.178/85Methyltransferase
orf16751WP_053684324.153/65LuxR-family transcriptional regulator
orf17229WP_042159102.183/88Hypothetical protein
orf18404WP_052718894.190/93Hypothetical protein
orf19295SCK58100.186/91Putative nuclease
orf20170WP_035838695.181/85MarR-family transcriptional regulator
orf21123WP_039639044.193/95Glyoxalase
orf22318WP_042157776.178/83DNA-3-methyladenine glycosylase 2 family protein
rf23190WP_042159103.197/99Hypotheticalprotein
orf24373WP_042159104.199/100ROK-familyglucokinase
orf25269WP_085927837.1100/100Sugar ABC transporter ATP-binding protein
orf26356WP_085927838.199/99Ribose ABC transporter permease
orf27337WP_042159107.199/100Sugar ABC transporter substrate-binding protein
orf28358WP_042159108.196/97Sugar ABC transporter substrate-binding protein
orf29258GAO11207.198/99GntR-family transcriptional regulator
orf30126WP_018092820.184/90Glyoxalase
orf31275WP_042159111.195/96Putative aminoacid ABC transporter
orf32219WP_085927844.199/992-dehydro-3-deoxy-phosphogluconate aldolase

Share and Cite

MDPI and ACS Style

García-Salcedo, R.; Álvarez-Álvarez, R.; Olano, C.; Cañedo, L.; Braña, A.F.; Méndez, C.; De la Calle, F.; Salas, J.A. Characterization of the Jomthonic Acids Biosynthesis Pathway and Isolation of Novel Analogues in Streptomyces caniferus GUA-06-05-006A. Mar. Drugs 2018, 16, 259. https://doi.org/10.3390/md16080259

AMA Style

García-Salcedo R, Álvarez-Álvarez R, Olano C, Cañedo L, Braña AF, Méndez C, De la Calle F, Salas JA. Characterization of the Jomthonic Acids Biosynthesis Pathway and Isolation of Novel Analogues in Streptomyces caniferus GUA-06-05-006A. Marine Drugs. 2018; 16(8):259. https://doi.org/10.3390/md16080259

Chicago/Turabian Style

García-Salcedo, Raúl, Rubén Álvarez-Álvarez, Carlos Olano, Librada Cañedo, Alfredo F. Braña, Carmen Méndez, Fernando De la Calle, and José A. Salas. 2018. "Characterization of the Jomthonic Acids Biosynthesis Pathway and Isolation of Novel Analogues in Streptomyces caniferus GUA-06-05-006A" Marine Drugs 16, no. 8: 259. https://doi.org/10.3390/md16080259

APA Style

García-Salcedo, R., Álvarez-Álvarez, R., Olano, C., Cañedo, L., Braña, A. F., Méndez, C., De la Calle, F., & Salas, J. A. (2018). Characterization of the Jomthonic Acids Biosynthesis Pathway and Isolation of Novel Analogues in Streptomyces caniferus GUA-06-05-006A. Marine Drugs, 16(8), 259. https://doi.org/10.3390/md16080259

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop